Cixutumumab ELISA Kit

Cixutumumab (IMC-A12) is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity for the treatment of solid tumors. This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from Dyax. Cixutumumab was well tolerated when used alone and in combination therapies, but its antitumor activity was low in the existing phase II clinical trials. An acceptable incidence of adverse effects supports further investigation of this drug, provided that it shows antitumor activity in combination with other drugs. Now, cixutumumab is involved in two cancer clinical trials, including esophageal cancer and breast cancer.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.